ScienceLife SciencesHealth & FitnessMedicine

PETRI DISH PERSPECTIVES

Manead Khin

Burma | Chicago
Scientist 🥼🧪🔬
Covering biotech, pharma, and healthcare companies shaping the world 🧬🏥🌎

Stream new episodes every THURSDAY!

https://linktr.ee/maneadkhin

#biotech #pharma #healthcare #podcast #petridishperspectives

Play

Open in

35 episodes
weekly
Avg 23 min
English

Support the show

Goes straight to the publisher. podnod takes nothing.

Support this Podcast

Episodes 35

Newest Oldest Longest

All15 Unplayed15 In progress0 Played0

Counted on this page — what you have heard stays on this device, so it is not something the list can be paged by.

S1 · E64
July 16 · 23 min
Episode 64: Conception Bio
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction. We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond. Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E63
July 9 · 23 min
Episode 63: Enveda Biosciences
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely untapped chemical library: nature. We'll trace the history of natural product drug discovery, from penicillin and paclitaxel to the AI revolution, dive into founder Viswa Colluru's vision of creating a searchable map of nature's chemistry, and explore how Enveda's platform is transforming plants, fungi, and microbes into tomorrow's medicines. We'll also discuss the company's growing clinical pipeline, why investors have poured hundreds of millions into the platform, and whether AI can finally solve one of drug discovery's oldest challenges. Because sometimes, the future of medicine isn't invented, it evolves. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Enveda #ArtificialIntelligence #AI #DrugDiscovery #Biotech #NaturalProducts #MachineLearning #Metabolomics #Pharmaceuticals #Healthcare #PrecisionMedicine #MedicinalChemistry #LifeSciences #Biotechnology #Innovation #ClinicalResearch #DrugDevelopment #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E62
July 2 · 24 min
Episode 62: Isomorphic Labs
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medicines are discovered. We'll dive into the origins of AlphaFold, the scientific vision of Nobel Prize-winning CEO Demis Hassabis, how AI is reshaping medicinal chemistry, and why pharmaceutical giants like Novartis and Eli Lilly are investing billions in AI-powered drug discovery partnerships. We'll also discuss the promise, challenges, and future of foundation models in biology, and whether AI can truly accelerate the journey from molecule to medicine. Because the next blockbuster drug may not be discovered by chance, it may be designed by an algorithm. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #IsomorphicLabs #DeepMind #AlphaFold #ArtificialIntelligence #AI #DrugDiscovery #Biotech #Healthcare #PrecisionMedicine #Pharmaceuticals #MachineLearning #ProteinFolding #DemisHassabis #NobelPrize #MedicinalChemistry #LifeSciences #Biology #Google #Alphabet #EliLilly #Novartis #FutureOfMedicine #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
June 30 · 10 min
June 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E61
June 25 · 23 min
Episode 61: Danaher
Send us Fan Mail In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Danaher became one of the biggest winners of the COVID-19 era. While biotech headlines focus on breakthrough drugs and billion-dollar acquisitions, Danaher quietly supplies the tools, diagnostics, manufacturing systems, and technologies that power modern medicine. From sequencing cancer genomes and producing monoclonal antibodies to manufacturing gene therapies and vaccines, Danaher sits behind the scenes enabling scientific innovation across the globe. We'll also discuss the leadership of Larry Culp, the company's role in the rise of biologics, gene therapies, and precision medicine, and the lessons Danaher offers about building value through infrastructure rather than blockbuster products. Because sometimes the companies changing healthcare aren't the ones discovering the drugs, they're the ones making discovery possible. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Danaher #Biotech #LifeSciences #Healthcare #Biopharma #Cytiva #PallCorporation #BeckmanCoulter #Diagnostics #GeneTherapy #CellTherapy #Biologics #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #LaboratoryScience #LarryCulp #BusinessPodcast #BiotechPodcast #HealthcareInnovation #Investing #Science #CorporateHistory #HealthcareBusiness Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E60
June 18 · 25 min
Episode 60: Hims & Hers
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E59
June 11 · 23 min
Episode 59: Illumina
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E58
June 4 · 23 min
Episode 58: UnitedHealthcare
Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the creation of Optum, and the acquisition strategy that turned UnitedHealth into far more than an insurance company. We also unpack the controversies surrounding prior authorizations, claim denials, Medicare Advantage investigations, antitrust concerns, and the growing public frustration with the American healthcare system. Finally, we examine one of the most shocking moments in modern corporate history: the assassination of CEO Brian Thompson in 2024, the national conversation it sparked, and what it revealed about the growing tension between healthcare corporations and the patients they serve. This is a story about scale, innovation, power, controversy, and the future of healthcare itself. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #UnitedHealthcare #UnitedHealthGroup #Optum #Healthcare #HealthInsurance #MedicareAdvantage #HealthcareInnovation #HealthcareBusiness #Biotech #Pharma #HealthTech #BrianThompson #CorporateStrategy #PetriDishPerspectives #HealthcarePolicy #DigitalHealth #ValueBasedCare #ManagedCare #HealthcareEconomics #BusinessPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
June 1 · 11 min
May 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industry has clearly shifted toward a model of integrated precision, prioritizing both the speed of research and the consolidation of complex manufacturing infrastructure. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E57
May 28 · 25 min
Episode 57: 23andMe
Send us Fan Mail This week on Petri Dish Perspectives, we unpack the story of 23andMe, the company that turned saliva kits into one of the largest human genetic databases in the world and brought genomics out of hospitals and into millions of homes. From its Silicon Valley origins under Anne Wojcicki to its rise as a consumer genetics pioneer backed by major investors, we explore how 23andMe built a direct-to-consumer model that reshaped public engagement with DNA. We break down the science behind SNP genotyping, the shift from ancestry testing to drug discovery partnerships with pharma giants like GSK, and the promise and limits of consumer-driven precision medicine. We also dive into the SPAC-era hype cycle, regulatory and FDA battles, privacy controversies around genetic data ownership, and the deeper ethical question at the heart of the company: who actually owns your biology once it’s been digitized? This is a story about genetics, identity, data, and the uneasy intersection of science and consumer tech. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #23andMe #Genetics #Biotech #DNA #Genomics #PrecisionMedicine #HealthcareInnovation #BioTech #Pharma #DataPrivacy #ConsumerGenomics #SPAC #DrugDiscovery #SciencePodcast #PetriDishPerspectives #Ancestry #DigitalHealth Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E56
May 21 · 23 min
Episode 56: Thermo Fisher
Send us Fan Mail This week on Petri Dish Perspectives, we’re diving into the story of Thermo Fisher Scientific, the company quietly powering nearly every corner of modern biotechnology. From its origins in scientific instrumentation to becoming a global life sciences infrastructure giant, we explore how Thermo Fisher built an empire through acquisitions, genomics, diagnostics, contract manufacturing, and the “picks-and-shovels” strategy behind biotech’s biggest breakthroughs. We also unpack the company’s role during COVID-19, its expansion into CDMO services, and why some of the most powerful companies in healthcare are often the ones nobody talks about. This is the story of the invisible engine behind modern biology and the company behind the companies. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #ThermoFisher #Biotech #LifeSciences #Biotechnology #Pharma #DrugDevelopment #Genomics #Diagnostics #CDMO #HealthcareInnovation #PrecisionMedicine #Science #Biopharma #PetriDishPerspectives #LaboratoryScience #SyntheticBiology #ThermoFisherScientific Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E55
May 14 · 23 min
Episode 55: Alnylam
Send us Fan Mail From the discovery of RNA interference to the first FDA-approved gene-silencing therapy, this week on Petri Dish Perspectives, we dive into the story of Alnylam Pharmaceuticals, the company that turned one of biology’s most powerful mechanisms into an entirely new class of medicine. We explore the science behind RNAi, the delivery challenges that nearly killed the field, the leadership of John Maraganore, and how partnerships with Novartis, Sanofi, Regeneron Pharmaceuticals, and Roche helped transform Alnylam from a risky platform biotech into a genetic medicines powerhouse. We also break down the development of Onpattro, Amvuttra, and the broader future of programmable medicine. This is the story of persistence, platform biology, and the rise of RNA therapeutics. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Biotech #Alnylam #RNAi #GeneticMedicine #Biopharma #RNAInterference #Onpattro #Amvuttra #RareDisease #DrugDevelopment #PrecisionMedicine #Biotechnology #HealthcareInnovation #Pharma #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E54
May 7 · 16 min
Episode 54: All about 340B
Send us Fan Mail In this episode of Petri Dish Perspectives, we break down the 340B Drug Pricing Program, a little-known but massively influential policy shaping how hospitals, pharmacies, and drug manufacturers operate today. Created under the Health Resources and Services Administration, 340B was designed to help safety-net providers stretch scarce resources and serve vulnerable patients. But over time, it has evolved into something much bigger. We unpack how the program actually works, why it’s become a financial cornerstone for many hospital systems, and the growing tension with pharmaceutical companies like Pfizer and Johnson & Johnson. From contract pharmacy battles to questions around transparency and patient benefit, the 340B ecosystem sits at the center of one of the most complex, and controversial, debates in healthcare economics. Because 340B isn’t just about drug discounts. It’s about who captures value in the healthcare system and who it’s really meant to serve. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #340B #HealthcarePolicy #Pharma #DrugPricing #HealthEconomics #Biotech #HealthcareInnovation #PetriDishPerspectives #USHealthcare #PolicyExplained Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
May 1 · 11 min
April 2026: Biotech & Pharma NEWS Roundup
Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for April 2026! This month was dominated by a high-stakes pivot toward oral obesity treatments, a massive consolidation of precision oncology platforms like ADCs and radiopharmaceuticals, and a structural shift toward AI-native drug discovery and in-vivo genomic medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters
S1 · E53
April 30 · 25 min
Episode 53: CAR-T Therapies
Send us Fan Mail What if cancer treatment wasn’t a drug but a living, evolving system inside your body? In this episode, we break down one of the most revolutionary innovations in modern medicine: CAR-T cell therapy. From its origins in academic labs to billion-dollar acquisitions by companies like Gilead Sciences, Bristol Myers Squibb, and Novartis, CAR-T represents a fundamental shift, from treating disease to programming the immune system. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #CAR-T #CellTherapy #Biotech #Oncology #Immunotherapy #CRISPR #HealthcareInnovation #Pharma #BiotechPodcast #PetriDishPerspectives #PrecisionMedicine #CancerResearch #FutureOfMedicine Support the show © 2026 The Perspective Bureau LLC. All rights reserved.
- Transcript
- Chapters

Showing 21–35 of 35 episodes